Form D · Biotechnology
Pearl Diagnostics, Inc.
Baltimore, MD · CIK 0001922830
Offering snapshot reported Apr 21, 2026 · SEC filing
- Reported sold
- $11.2M Offering amount: $11.2M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $56.5K Reported outside-investor minimum
- First sale
- Mar 19, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 21, 2026 | Initial | $11,150,000 | No comparison | 21 | SEC filing |
| Jun 17, 2022 | Initial | $3,525,000 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-581278
Source: Form D, filed Apr 21, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Cammack | Director |
| Eric Gornstein | Director, Executive |
| Kieren Marr | Director, Executive |
| Brad Spellberg | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1812 Ashland Avenue Suite G32
Baltimore, MD, 21205
Baltimore, MD, 21205